Articles tagged with: Revlimid
The results of a small British study may lead to fewer myeloma patients suffering from diarrhea while taking Revlimid.
In a short article published last week, researchers from the Royal Marsden Hospital in London report that a condition known as “bile acid malabsorption” appears to be a frequent cause of the diarrhea experienced by some patients during treatment with Revlimid (lenalidomide).
The researchers also found that the bile acid malabsorption and resulting diarrhea in these patients can be addressed in two ways.
For some patients, reducing consumption of …
Amgen this morning announced initial results of its Phase 3 “ASPIRE” trial comparing Kyprolis-Revlimid-dexamethasone to Revlimid-dexamethasone in patients with relapsed multiple myeloma.
Patients in the trial who received the Kyprolis-Revlimid-dexamethasone combination (KRd) had significantly longer progression-free survival (26.3 months) than patients who received only Revlimid and dexamethasone (Rd) (17.6 months).
There was also a trend in the results toward improved overall survival among the patients who received KRd versus those who did not. However, the difference is not yet statistically significant.
The results of the trial are important for two …
It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.
Quite a few presentations caught one’s eye.
We finally saw the results of the much awaited PANORAMA-1 study investigating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexamethasone compared to Velcade and dexamethasone alone.
Another study looked at …
French researchers earlier this week published updated results of a small Phase 2 clinical trial testing the combination of Revlimid, Velcade, and dexamethasone (RVD) in newly diagnosed multiple myeloma patients.
The researchers found that RVD, when given before and after stem cell transplantation – and when followed by maintenance therapy with Revlimid – led to very deep treatment responses and significant survival rates.
The 31 newly diagnosed patients in the French trial initially were treated with three cycles of RVD therapy. Next, the trial participants underwent autologous (own) stem cell …
This year’s American Society of Clinical Oncology (ASCO) annual meeting began yesterday morning in Chicago and will run through Tuesday.
Myeloma-related presentations were made during two sessions yesterday.
One session was designed to better educate physicians about personalized therapy for elderly patients with lymphoid malignancies. During that session, Dr. Tanya Marya Wildes from the Washington University School of Medicine in St. Louis talked about how to navigate treatment options for older multiple myeloma patients.
The key myeloma-related research presented yesterday was made public during a poster session in the afternoon …